Question follow-through · 110575

Vitamin D: Deficiency Diseases

To ask the Secretary of State for Health and Social Care, if he will ask the Scientific Advisory Committee on Nutrition to review whether current vitamin D supplementation recommendations (a) adequately serve all population groups and (b) take adequate ac

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department of Health and Social Care
Tabled
3 Feb 2026
Target answer date
5 Feb 2026
Answer
11 Feb 2026 · 8 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

More questions by this MP on Health and care

Shared topic keywords suggest a connection; they do not establish a follow-up.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

  1. 3 Feb 2026

    Question tabled

    To ask the Secretary of State for Health and Social Care, if he will ask the Scientific Advisory Committee on Nutrition to review whether current vitamin D supplementation recommendations (a) adequately serve all population groups and (b) take adequate ac

  2. 5 Feb 2026

    Target answer date

    Date supplied by the official written-questions record.

  3. 11 Feb 2026

    Answer published

    In 2016, the Scientific Advisory Committee on Nutrition (SACN) published a robust assessment of the evidence on vitamin D and a wide range of health outcomes resulting in the current advice for everyone to take a 10 microgram, or 400 international units, ...

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Disability: Finance

6 Feb 2026 · To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that funding for wheelchair users is adequate to meet essential needs, including equipment and specialist support.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Wheelchairs: Health Services

6 Feb 2026 · To ask the Secretary of State for Health and Social Care, what statistics he has on the demand for and use of wheelchairs; and how that data informs NHS England’s commissioning of appropriate services.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Wheelchairs: Health Services

6 Feb 2026 · To ask the Secretary of State for Health and Social Care, whether he plans to make the recently developed service specification guidelines for wheelchair services mandatory across England.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Wheelchairs: Health Services

6 Feb 2026 · To ask the Secretary of State for Health and Social Care, whether he plans to ensure that NHS organisations and contracted wheelchair service providers are subject to more rigorous, mandatory regulation.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Cancer: Screening

10 Feb 2026 · To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the expansion of diagnostic genomic testing for cancer is accompanied by timely NHS access to targeted therapies identified by that testing, including where s

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Rare Cancers: Health Services

10 Feb 2026 · To ask the Secretary of State for Health and Social Care, what provision the National Cancer Plan will make for orphan drug pathways for patients with rare cancers requiring personalised treatment plans; and how those pathways will differ from existing co

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Cancer: Drugs

10 Feb 2026 · To ask the Secretary of State for Health and Social Care, what steps he is taking to align NICE appraisal timelines, MHRA regulatory pathways and NHS commissioning decisions to support the delivery of personalised cancer medicines.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Rare Cancers: Health Services

10 Feb 2026 · To ask the Secretary of State for Health and Social Care, with reference to page 75 of the policy paper entitled A National Cancer Plan for England: delivering world class cancer care, whether it is his policy that patients with rare cancers should be off

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Radiotherapy: Medical Equipment

20 Feb 2026 · To ask the Secretary of State for Health and Social Care, how much of the £70 million allocated in the Autumn Budget 2024 for new linear accelerator (LINAC) machines has been spent to date; how many new LINAC machines have been procured with that funding;

Unreviewed candidateSame MP and department; topic relationship is unreviewed

National Cancer Board

20 Feb 2026 · To ask the Secretary of State for Health and Social Care, with reference to Action 21 of the National Cancer Plan, when his Department expects the reformed National Cancer Board to be established.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

National Cancer Board

20 Feb 2026 · To ask the Secretary of State for Health and Social Care, with reference to Action 21 of the National Cancer Plan, what appointment process will be used to select the independent representative who will co chair the reformed National Cancer Board.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Rare Cancers: Medical Treatments

25 Feb 2026 · To ask the Secretary of State for Health and Social Care, what steps he is taking to help support access to genomically-matched targeted therapies for patients with rare cancers, where genomic testing identifies a suitable option but large-scale clinical